Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Q3 2019 Earnings Presentation
21 slides from Getinge Ab Class B's earnings presentation, Oct 18, 2019
Slide 1: Q3 Report 2019
Q3 Report 2019 Mattias Perjos, President and CEO Lars Sandström, CFO October 18, 2019
Slide 2: Key takeaways – performance
Key takeaways – performance Q3 2019 49.8 • Sales growth continues 49.4 R12 Gross Margin (adj) % • Increased Gross Margin • Increased EBITA Margin • Positive development on 12.0 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Working Capital and strong Cash Flow 11.6 R12 EBITA Margin (adj) % • Leverage reduced to 3.
Slide 3: Key takeaways – events
Key takeaways – events Q3 2019 • Starting to see positive impact from restructuring activities in H1 2019 • Increased volumes and productivity gains in the supply chain • Remediation cost impacting negatively • Positive trajectory on recent premium launches, such as the ventilator Servo-u 4.0 • New
Slide 4: Organic growth continues
Organic growth continues Growing faster than the average in addressable market Americas EMEA APAC Global Order Intake +3.5% Net Sales +4.8% Getinge Q3 Report 2019 October 18, 2019 Page 4
Slide 5: Contribution in Order Intake
Contribution in Order Intake Bridge Q3 2018 - Q3 2019 Organic change +6.9% +10.5% -3.0% +3.5% 30 78 397 6,678 6,173 MSEK Q3 2018 Acute Care Therapies Life Science Surgical Workflows Q3 2019 Getinge Q3 Report 2019 October 18, 2019 Page 5
Slide 6: Contribution in Net Sales
Contribution in Net Sales Bridge Q3 2018 - Q3 2019 Organic change +3.6% +2.9% +7.0% +4.8% +283 Currency impact, MSEK 33 244 276 6.8 6,236 Organic growth, % 5,683 MSEK 3.4 Q3 2018 Acute Care Life Science Surgical Workflows Q3 2019 Capital Consumables Therapies Getinge Q3 Report 2019 October 18, 2019
Slide 7: Gross Margin development Q3 2019
Gross Margin development Q3 2019 Bridge Q3 2018 - Q3 2019 Adj GM, % Q3 2019: 57.4 40.4 43.3 50.8 (Q3 2018): (54.1) (36.3) (40.9) (47.9) Gross Margin impact 33 154 Volume 263 IFRS 16 3,171 2,721 Currency MSEK Product mix Regional mix Q3 2018 Acute Care Life Science Surgical Workflows Q3 2019 Therapie
Slide 8: Financial development
Financial development Getinge Q3 Report 2019 October 18, 2019 Page 8
Slide 9: Adjusted EBITA
Adjusted EBITA Bridge Q3 2018 – Q3 2019 Improved margin 7.7% 10.9% +1.0 pp Currency +239 +2.0 pp GP -47 -0.1 pp OPEX -25 -15 +0.2 pp Depreciation -19 +0.1 pp IFRS 16 450 -105 MSEK 677 438 Q3 2019 Adj Gross profit Adj Selling Adj Admin Adj R&D Other D&A Q3 2019 Getinge Q3 Report 2019 October 18, 2019
Slide 10: Adjusted EBITA
Adjusted EBITA Bridge Q3 2018 – Q3 2019 +239 84 -43 + 93 16 Currency impact, MSEK 677 182 438 MSEK Q3 2018 Acute Care Life Science Surgical Workflows Common Group Q3 2019 Therapies Functions and other (incl eliminations) Getinge Q3 Report 2019 October 18, 2019 Page 10
Slide 11: Control on OPEX
Control on OPEX Number of FTE’s continue to decrease in the underlying business -335 FTE’s since the peak OPEX in relation to Net Sales since peak 10,900 33.8 -335 FTE -1.0 pp 10,800 10,700 33.4 10,600 33.0 10,500 10,400 +48 32.6 10,300 FTE net increase in 10,200 production, remedi- ation and sales,
Slide 12: Stable cash flow development
Stable cash flow development Q3 2019 – continued positive development on working capital and leverage at 3.0 • Improved operating profit Jul-Sep Jul-Sep Jan-Sep Jan-Sep Jan-Dec SEK M 2019 2018 2019 2018 2018 • Tax recovery in Q3 2018 impacting year on Cash flow before changes in working capital 719
Slide 13: Stable cash flow development
Stable cash flow development Working Capital is declining in days and in absolute terms Working Capital Days continue to improve Working Capital is decreasing despite strong sales growth 135 4.8 130 -15 days 125 120 115 110 0 18-Sep 19-Sep 18-Mar 19-Mar 18-Jun 19-Jun 17-Dec 18-Dec -7.1 Working Capit
Slide 14: Outlook
Outlook Getinge Q3 Report 2019 October 18, 2019 Page 14
Slide 15: Outlook 2019
Outlook 2019 2-4% Organic Net Sales Growth Getinge Q3 Report 2019 October 18, 2019 Page 15
Slide 16: Summary
Summary Getinge Q3 Report 2019 October 18, 2019 Page 16
Slide 17: Key takeaways
Key takeaways Summary Q3 2019 • Sales growth continues • Increased Gross Margin • Increased EBITA Margin • Positive development on Working Capital and strong Cash Flow • Leverage reduced to 3.0 Getinge Q3 Report 2019 October 18, 2019 Page 17
Slide 18: Q&A
Q&A Getinge Q3 Report 2019 October 18, 2019 Page 18
Slide 19: Thank you
Thank you Getinge Q3 Report 2019 October 18, 2019 Page 19
Slide 20: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 21: GETINGE
Se a GETINGE PASSION FOR LIFE